A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
Niese
D
D
Department of Clinical Research and Development, Immunology, Sandoz Pharma Ltd, Basle, Switzerland.
D000284:Administration, Oral; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D003971:Diastole / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D013256:Steroids / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine; D003404:Creatinine; D001379:Azathioprine